Literature DB >> 6101738

Pathogenesis and natural course of primary osteoporosis.

H P Kruse, F Kuhlencordt.   

Abstract

A new concept of the pathogenesis and natural course of osteoporosis is described, based on histomorphometric evaluation of iliac crest bone biopsies of 108 patients with untreated primary osteoporosis. It is suggested that primary osteoporosis spontaneously runs a three-phase course: during the initial period of negative bone balance, bone mass falls below the normal range; during the second phase bone mass remains consistently below age-related normal values; in the third phase restitution of osteoporosis is introduced by a positive bone balance. It is suggested that only about a quarter of patients with a skeletal mass below the age-related normal range have true primary osteoporosis; the remaining three-quarters may have secondary forms of osteoporosis where the underlying disease responsible for the bone loss had been missed before the osteoporosis was diagnosed.

Entities:  

Mesh:

Year:  1980        PMID: 6101738     DOI: 10.1016/s0140-6736(80)90779-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Estimated long-term effect of calcitonin treatment in acute osteoporotic spine fractures.

Authors:  H Resch; P Pietschmann; R Willvonseder
Journal:  Calcif Tissue Int       Date:  1989-10       Impact factor: 4.333

2.  Gastrointestinal calcium absorption and dietary calcium load: relationships with bone remodelling in vertebral osteoporosis.

Authors:  M Tellez; M E Arlot; E B Mawer; A Diaz; R Hesp; P Hulme; C Edouard; J R Green; P J Meunier; J Reeve
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

3.  Temporal variations in iliac trabecular bone formation in vertebral osteoporosis.

Authors:  M E Arlot; J N Bradbeer; C Edouard; J R Green; R Hesp; J P Roux; P J Meunier; J Reeve
Journal:  Calcif Tissue Int       Date:  1993-01       Impact factor: 4.333

4.  1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women.

Authors:  R J Duda; R Kumar; K I Nelson; A R Zinsmeister; K G Mann; B L Riggs
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

5.  Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment.

Authors:  Qiang Xu; Ping Zhan; Xiaofeng Li; Fengbo Mo; Huaen Xu; Yuan Liu; Qi Lai; Bin Zhang; Min Dai; Xuqiang Liu
Journal:  J Cell Mol Med       Date:  2021-10-15       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.